Kornimate/medical-research-clean huggingface dataset:
nutritional strategies to increase nitric oxide signaling in raynaud's phenomenon

Conditions: Raynaud Phenomenon

Summary: the investigators aim at comparing the efficacy of a 2 weeks supplementation by l-citrulline or beetroot juice to l-citrulline placebo or denitrated beetroot juice respectively on raynaud's phenomenon severity. raynaud's phenomenon severity will be assessed through the raynaud condition score, daily frequency of attacks or cumulative attack duration (expressed as min) daily collected by patients in a diary. each volunteer will choose his own main outcome among these 3 criteria.

raynaud's phenomenon (rp) is a clinical condition that follows an exaggerated vasoconstriction of extremities in response to a cold or emotional stress. microvascular dysfunction and alteration of the endothelial no-dependent vasodilatation pathway through no synthases (nos) represents one of the main mechanisms. a pharmacological treatment in rp is proposed to patients when conservative measures are not efficient enough to control the symptoms: calcium channel blockers remains the first line, phosphodiesterase type 5 inhibitors as a second line treatment, while intravenous iloprost remains restricted to patients with digital ischaemia. vasodilator therapies are commonly associated with side effects due to the non-specific systemic vasodilation that often result in permanent discontinuation. many patients prefer complementary and alternative therapies, but none has proven its efficacy. therefore, there is still room for improvement in the treatment of rp, and research is needed in this area.

Eligibility criteria:
inclusion criteria: * bmi \> 18 * active raynaud's phenomenon characterized by a clinical history of raynaud's 1. primary rp or secondary to limited (lssc), limited or diffuse cutaneous scleroderma (lcssc or dcssc) according to the criteria of leroy and medsger. 2. at least 1 rp attacks per week and a specific finger patient picture in rp attack (assessed over the 2 weeks preceding inclusion) * stable disease over the previous two months (i.e. recent diagnosis of ssc will be excluded) * patients insured by a social security scheme or beneficiaries of such a scheme * patients who have dated and signed the informed consent form exclusion criteria: * uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled angina * haemodynamic instability * pregnancy (or considering pregnancy in next 4 months) or breast feeding * subject in an exclusion period from another study, * subject under administrative or judicial supervision * subject not able to be contacted in case of emergency

Keywords: l-citrullin beetroot juice raynaud's phenomenon
r-da-edoch versus r-ceop90, with/without upfront auto-hsct in young patients with high-risk dlbcl

Conditions: Diffuse Large B-cell Lymphoma

Summary: patients initially are randomized into 2 arms: arm i: r-da-epoch; arm ii: r-ceop90; patients who achieved complete remission (cr) or partial remission (pr) after 6 cycles of r-da-epoch (arm i) or r-ceop90 (arm ii), continue to have 2 more cycles for consolidation in each arm, or undergo stem cell harvest and auto-hsct following standard institutional protocols.

patients initially are randomized into 2 arms: arm i: r-da-epoch; arm ii: r-ceop90; patients who achieved complete remission (cr) or partial remission (pr) after 6 cycles of r-da-epoch (arm i) or r-ceop90 (arm ii), continue to have 2 more cycles for consolidation in each arm, or undergo stem cell harvest and auto-hsct following standard institutional protocols. the overall purpose of the study is to determine if r-ceop90 followed by auto-hsct has similar efficacy compared to that with r-da-epoch.

Eligibility criteria:
inclusion criteria: * age 16-60 years * newly diagnosed dlbcl * no previous treatment with chemotherapy and/or radiation therapy of dlbcl * presence of 2 or more signs of unfavorable prognosis: aaipi≥2 or aaipi=1 with bulk (≥7.5cm) * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * life expectancy of ≥6 months * adequate hematological function * offer informed consent exclusion criteria: * transformation of mature cell lymphomas in dlbcl * pretreated dlbcl * hiv-associated dlbcl * concomitant other cancer * congestive heart failure, unstable angina, severe cardiac arrhythmias and conduction disturbances, myocardial infarction * renal insufficiency (serum creatinine greater than 0.2 mmol/l) (except cases with specific kidney infiltration, urinary tract compression by tumor conglomerate or presence of uric acid nephropathy due to massive cytolysis syndrome) * liver failure (except cases with liver tumor infiltration), acute hepatitis or active phase of chronic hepatitis b or c with serum bilirubin greater than 1.5 standards, alanine aminotransferase (alt) and aspartate aminotransferase (ast) greater than 3 standards, prothrombin index less than 70% * severe pneumonia (except cases with specific lungs infiltration), accompanied by respiratory failure (dyspnea \> 30 in min., hypoxemia less than 70 mm hg, when it is impossible to compensate situation in 2-3 days) * life-threatening bleeding (gastrointestinal, intracranial), with exception of bleeding due to tumor infiltration of organs (stomach, intestines, uterus, etc.) and disseminated intravascular coagulation due to underlying disease complications after their successful conservative treatment * severe mental disorders (delusions, severe depressive syndrome and other manifestations of productive symptoms) not related with specific infiltration of central nervous system * decompensated diabetes * pregnancy

Keywords: dlbcl, r-da-epoch, r-ceop90, auto-hsct
two therapeutic strategies in first-line in patients with epithelial advanced ovarian cancer

Conditions: Ovarian Cancer, Epithelial

Summary: chimovip is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

this is a randomized phase ii study, open-label and multicentric. after initial intervention (debulking surgery or diagnostic surgery) patient will randomized in the study according to completeness of cytoreduction (cc) score (cc0 or cc\>1).

Eligibility criteria:
inclusion criteria: * histologically confirmed advanced (figo stage iii or iv) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. pleural cytology has to be performed in patients with pleural effusion. * initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion * age ≥18 and \< 75 years old. * eastern cooperative oncology group (ecog) performance status ≤ 2 before surgery (ecog ≤ 1 and lee score \ 70 years old). * adequate blood count (test realized in the past 14 days before inclusion) : neutrophils \> 1500/mm3, platelets \> 150 000/mm3. * creatinine clearance mdrd ≥ 60 ml/min * registration in a national health care system (cmu included). * signed and dated informed consent. exclusion criteria: * figo stage iv extra-abdominal disease, with the exception of lymph nodes and pleural invasion. * patient having received previous chemotherapy for ovarian cancer. * left ventricular ejection fraction \< 50% before chemotherapy initiation * other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted) * concomitant administration of prophylactic phenytoin or live attenuated viral vaccines such as yellow fever vaccine, * patients with known hypersensitivity to any component of study drug * patients without motivation or capacity to respect study requirements and constraints * pregnancy or breast feeding women

Keywords: intraperitoneal intravenous completeness of cytoreduction score carboplatin epirubicin paclitaxel cisplatin
cognitive and behavioral dysexecutive syndrome in multiple system atrophy

Conditions: Multiple System Atrophy

Summary: the main objective of the study is to compare the score to the behavioral dysexecutive syndrome inventory (bdsi) between parkinsonian multiple system atrophy msa-p patients and cerebellar multiple system atrophy (msa-c) patients matched on disease duration, age (± 7 years) and sex .

multiple system atrophy (msa) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. according to the consensus criteria for the diagnosis of msa, the presence of dementia is considered an exclusion criteria. however, several studies have reported cognitive impairment in patients with msa, dominated by a dysexecutive syndrome. some studies have compared the cognitive profile of msa-p patients and msa-c but any have studied the behavioral dysexecutive syndrome in this population. in 2010, the greffex has established criteria for dysexecutive syndrome and described two distinct parts: the dysexecutive syndrome and cognitive behavioral dysexecutive syndrome. our clinical impression is that according to the type of msa, the dysexecutive syndrome seems to be different : the msa-p patients seem to have a cognitive dysexecutive syndrome and the msa-c patients a behavioral dysexecutive syndrome. we want to compare the bdsi score between msa-p patients and msa-c patients matched on disease duration, age and sex the specific involvement of the cerebellum in behavioral disorders could explain the behavioral differences experienced by clinicians caring for these patients but never demonstrated. the presence of these disorders could have an impact on the relationship between the patient and the caregiver. in addition, few studies have correlated with cognitive imagery data. therefore, the exact areas involved in cognitive and behavioral msapatients remain poorly understood.

Eligibility criteria:
inclusion criteria: * patients suffering from "probable" msa according to clinical consensus criteria (gilman et al, 2008), * age \>30 * written informed consent * patient covered by the national health system * the presence of an informant * blood negative dosage of the hormone béta-hcg for the women old enough to procreate exclusion criteria: * umsars iv score \> 4 points * pregnant woman (blood positive dosage of the hormone béta-hcg) or breast feeding * patient under tutelage * patient unable to give consent * against indication to perform an mri

Keywords: dysexecutive syndrome multiple system atrophy imaging study
early uvfp management based on neurological evidences (uvfp = unilateral vocal fold paralysis)

Conditions: Unilateral Vocal Cord Paralysis

Summary: the aim of this study is to understand how early intervention could impact reinnervation of the recurrent laryngeal nerve (which innervates the vocal cord), recovery of mobility of the paralyzed vocal cord and / or vocal recovery in the case of unilateral vocal fold paralysis. to achieve this goal we must therefore carry out a complete outcomes assessment of different intervention methods (voice therapy and injection laryngoplasty), which are offered to uvfp (unilateral vocal fold paralysis) patients in the early stage (\< 3 months). their respective impacts on the central and peripheral nervous system and on the voice quality will be assessed, taking into account factors related to the severity of the paralysis.


Eligibility criteria:
inclusion criteria: - unilateral paralysis in abduction of the vocal cords may be included in the study. exclusion criteria: * wear a pacemaker or other implanted devices (prostheses ...). * wear metal clips, metal in the head, or an adjustable brain drain. * wear non-removable dental appliances (except fillings). * wear cardiac valve prostheses. * have worked the metals. * have a tattoo containing metal particles. * have implanted jewelry (e.g., piercing). * being prone to epileptic seizures. * take medications that alter cortical excitability. * have had a brain surgery. * suffer from intracranial hypertension. * be pregnant or breastfeeding recently. * present allergies that are incompatible with the experimental protocol. * have an abnormal hearing loss in view of their age, identified with tonal and / or vocal audiometry.
effect of sublimated mare milk supplement on gut microbiome in psoriasis patients

Conditions: Psoriasis

Summary: this study evaluates the effect of dietary supplement consisting of sublimated mare milk on intestinal microbiota among psoriasis and healthy participants.

the gut microbiome is believed to play an important role in the immune system regulation, since intestines are the largest lymphoid organ in a human body. deviations from healthy composition of intestinal flora are associated with various diseases including allergy and autoimmunity. psoriasis is the one of the long-lasting autoimmune diseases that is characterized by patches on the skin and further health complications throughout the life. however, lack of studies does not allow proper evaluation of role of gut microbiome in psoriasis patients. therefore, potential interplay between gut microbiome and immune system in psoriasis would be studied in this clinical trial. particularly, the investigators hypothesize that sublimated mare milk supplement can have an impact on gut immune system and gut microbiome composition in the psoriasis patients. in this trial, there will be two parallel groups: crossover psoriasis patients (standard treatment first for 3 months, next 3 months standard treatment plus sublimated mare milk supplement) and healthy volunteers group. subsequently, association of intestinal flora with immune status will be analyzed and compared between these groups.

Eligibility criteria:
inclusion criteria. inclusion criteria for experimental group: * patients with a verified diagnosis of moderate to severe psoriasis * aged 30 to 45 years * absence of an allergic reaction to dairy products * lack of prescription of antibacterial drugs for the last 3 months prior to admission * willingness to consent to participate in the study inclusion criteria for healthy volunteers group. * patients with no diagnosis of psoriasis * aged 30 to 45 years exclusion criteria: * presence of chronic dermatoses, diseases of the organs of the gastrointestinal tract * presence of severe concomitant diseases of the kidneys, liver, cardiovascular, respiratory and other body systems, oncological, mental health and decompensated endocrine diseases, tuberculosis, and hiv infection * pregnancy and/or lactation * patient involvement in other clinical trials within the last 3 months * refusal to participate in the study

Keywords: mare milk gut microbiome psoriasis immune markers
multicenter study on the evaluation of adherence, persistence and efficacy of treatment with inclisiran in italy

Conditions: Hypercholesterolemia

Summary: evaluation of adherence, persistence and efficacy of treatment with inclisiran in a real-life italian population


Eligibility criteria:
inclusion criteria: * patients under inclisiran treatment exclusion criteria: * age \ 80 years * patients who refuse to participate and to sign informed consent
neural correlates of tactile prediction

Conditions: Neurodevelopmental Disorders; Premature Birth

Summary: this project aims to measure repetition suppression and tactile prediction using high-resolution electroencephalography in preschoolers, in order to describe the responses as a function of age, gestational age of birth and the presence of a neurodevelopmental disorder. we will include 100 children aged 2 or 6 years: 25 2-year-olds born prematurely, 25 2-year-olds born at term, 25 6-year-olds with typical development and 25 6-year-olds with neurodevelopmental disorders. we will perform several behavioral evaluations to analyze the results in view of the quality of development.

we will include 100 children aged 2 or 6 years: 25 2-year-olds born prematurely, 25 2-year-olds born at term, 25 6-year-olds with typical development and 25 6-year-olds with neurodevelopmental disorders. children will be recruited from local schools and institutions. birth will be considered premature if children were born before 36 weeks of gestational age. children will be considered as having neurodevelopmental disorder if they receive medical and/or paramedical care at the time of measurement for neurodevelopmental disorder, including autism spectrum disorder, attention deficit with or without hyperactivity, tics, learning disorders, but all participants must be attending school at the time of measurement. children will come to the lab for a 2 hours session with their parents, during which they will undergo movement, attention and executive functions evaluations. parents will fill out questionnaires evaluating their child's executive functioning and sensory profile in home/everyday settings. children will then be equipped with 128-channels electroencephalography and proposed two tests : a modified attention network task and a tactile prediction task. we will calculate correlations between evoked potential amplitudes during the tactile prediction trials and inhibitory conflict trials. results will be analysed in the light of age, gestational age at birth, ecological and psychometric evaluations, and neurodevelopmental status.

Eligibility criteria:
inclusion criteria: * age 24 to 35 or 72 to 83 months * born prematurely or term, with or without neurodevelopmental disorders (see arms) * parental informed consent * attending school exclusion criteria: * severe iq deficit or language impairment * psychotropic medication
effect of the anticholinergic drug burden on postoperative delirium in elderly chinese patients: a nested case-control study

Conditions: Delirium - Postoperative

Summary: this study aims to investigate the association between preoperative anticholinergic drugs burden and postoperative delirium in elderly chinese patients.


Eligibility criteria:
inclusion criteria: * patients over 65 years; undergoing general anesthesia; inpatients who had surgery between aprill 1, 2020 and aprill 1, 2022. exclusion criteria: * asa grade v; preoperative mini-mental state examination (mmse) score \ 5% missing data.
walking exercise and nutrition to reduce diabetes risk for you (wendy)

Conditions: Diabetes; Gestational Diabetes Mellitus

Summary: the prevalence of gestational diabetes mellitus (gdm) in australia is approximately 5%-8%, with up to one third of all parous women who develop type 2 diabetes having a previous history of gdm. research to determine strategies to delay or prevent the development of or progression to diabetes is vital, particularly in population groups that are at higher risk, such as gdm, and overweight women (bmi\>=25). currently, follow-up or post-partum support for women who develop gdm is limited to advice to complete a 6 week post-partum oral glucose tolerance test to exclude overt diabetes, to be repeated annually. a pilot randomized controlled trial (rct) conducted at mater mothers hospital suggested that a post-partum intervention designed to increase physical activity in women with previous gdm may be feasible. a recent study in the united states recruited women with recent gdm into an rct where the control group received usual care and the intervention group received a web based walking program. although the results of this study are limited, they did show an increase in pedometer steps/day between baseline and end of study. dietary intervention has been proven to increase probability of weight loss, so a strategy of combining both a pedometer and nutrition based program may prove to be more successful for long term improvement of a healthy lifestyle to prevent type 2 diabetes. study hypothesis: a pedometer based intervention to encourage physical activity, combined with nutrition coaching in women with recent gdm and bmi \>= 25 will result in increased weight loss, improved insulin sensitivity and increased physical activity when compared with standard care.


Eligibility criteria:
inclusion criteria: diagnosis of gestational diabetes mellitus and given birth in the preceding 6 months to 3 years; 18 years of age or older; bmi \>= 25; routine access to a computer; adequate computer skills to navigate websites and email; speak and understand english well enough to participate in the study exclusion criteria: currently pregnant or planning to become pregnant in the next year; current diabetes; currently taking medications that interfere with glucose metabolism
a randomized controlled trial with resolute onyx in one month dual antiplatelet therapy (dapt) for high-bleeding risk patients

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to evaluate the clinical safety and effectiveness of the resolute onyx stent in subjects deemed at high risk for bleeding and/or medically unsuitable for more than 1 month dapt treatment receiving reduced duration (1 month) of dapt following stent implantation.


Eligibility criteria:
inclusion criteria: * age ≥ 75 years old * any prior documented intracerebral bleed * any documented stroke in the last 12 months * hospital admission for bleeding during the prior 12 months * non-skin cancer diagnosed or treated ≤3 years * planned surgery within the next 12 months * renal failure defined as: creatinine clearance \<40 ml/min * thrombocytopenia (plt \<100,000/mm3) * severe chronic liver disease defined as: subjects who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice exclusion criteria: * pregnant and breastfeeding women * subjects requiring a planned pci procedure after 1 month of index procedure * active bleeding at the time of inclusion * cardiogenic shock * a known hypersensitivity or contraindication to aspirin, heparin and bivalirudin, p2y12 inhibitors, mtor inhibiting drugs such as zotarolimus, biolimus a9 (or its derivatives), cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer coatings (eg, biolinx™), stainless steel (or other metal ions found in 316l stainless steel), zinc, or a sensitivity to contrast media, which cannot be adequately pre-medicated. * pci during the previous 6 months for a lesion other than the target lesion of the index procedure * participation in another clinical study within 12 months after index procedure * subjects with life expectancy of less than 2 years